4-[5-[N-(2,4-二氧代咪唑烷-1-基)亚氨代甲基]-2-呋喃基]苯甲腈 | 14663-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: 4-[5-[N-(2,4-二氧代咪唑烷-1-基)亚氨代甲基]-2-呋喃基]苯甲腈
• 英文名称: 1-[5-(p-cyanophenyl)furfurylideneamino]hydantoin
• 英文别名: 1-((5-(p-Cyanophenyl)-2-furanyl)methyleneamino)hydantoin；4-[5-[(E)-(2,4-dioxoimidazolidin-1-yl)iminomethyl]furan-2-yl]benzonitrile
• CAS: 14663-27-5
• 化学式: C₁₅H₁₀N₄O₃
• 分子量: 294.269
• InChiKey: VYLIHXCXXMSMOH-CAOOACKPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  98.7
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  Boc-beta-丙氨酸 、 氯甲酸异丁酯 、 4-[5-[N-(2,4-二氧代咪唑烷-1-基)亚氨代甲基]-2-呋喃基]苯甲腈 、 三乙胺 、 盐酸 、 溶剂黄146 以62%的产率得到
  参考文献：
  名称：

  WESSELS, F. L.;ELLIS, K. O.;WHITE, R. L. ,, JR, J. PHARM. SCI., 1981, 70, N 9, 1088-1090

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲醛基呋喃-2-硼酸 在 盐酸 、 bis-triphenylphosphine-palladium(II) chloride 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 4-[5-[N-(2,4-二氧代咪唑烷-1-基)亚氨代甲基]-2-呋喃基]苯甲腈
  参考文献：
  名称：

  Dantrolene analogues revisited: general synthesis and specific functions capable of discriminating two kinds of Ca2+ release from sarcoplasmic reticulum of mouse skeletal muscle

  摘要：

  The general synthesis of dantrolene analogues with various substituents on its phenyl ring has been developed via palladium-catalyzed cross-coupling reactions, the Stille or Suzuki reaction, as the key step. The effects of synthesized analogues have been evaluated by two kinds of Ca2+ release modes from sarcoplasmic reticulum (SR) of mouse skeletal muscle fibers based on: (1) the measurement of twitch contraction caused by the physiological Ca2+ release (PCR) of intact skeletal muscle and (2) the rate of Ca2+-induced Ca2+ release (CICR) in saponin-treated skinned muscle fibers. Although dantrolene, a lead compound, inhibits both twitch contraction and CICR, some structurally modified analogues exhibit one or the other of these effects. The methoxy congener, GIF-0185, potently inhibits the twitch contraction without affecting the CICR, while GIF-0166 and GIF-0248, the ortho-nitro regioisomer and ortho, ortho-dinitro substituted analogues, respectively, doubly potentiate the CICR exclusively. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(02)00600-4

文献信息

• Co-solvent compositions and methods for improved delivery of dantrolene therapeutic agents
  申请人：US Worldmeds LLC

  公开号：EP2583670A1

  公开（公告）日：2013-04-24

  The present invention provides for methods of using terf-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.

  本发明提供了在配制和生产低溶解度药剂时使用特氟醇（TBA）助溶剂体系的方法。本发明还提供了使用新型助溶剂体系制成的药物组合物。在一个实施方案中，本发明提供了一种用于静脉注射的丹曲林钠（DS）制剂（DS-IV）的制作方法。这种瞬时重组的 DS-IV 产品极大地改进了手术期间恶性高热病人的药物治疗。
• CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPEUTIC AGENTS
  申请人：US Worldmeds LLC

  公开号：EP2219605A1

  公开（公告）日：2010-08-25
• Co-Solvent Compositions and Methods for Improved Delivery of Dantrolene Therapeutic Agents
  申请人：Malkawi Ahmad

  公开号：US20090093531A1

  公开（公告）日：2009-04-09

  The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
• CO-SOLVENT COMPOSITIONS AND METHODS FOR IMPROVED DELIVERY OF DANTROLENE THERAPUTIC AGENTS
  申请人：Malkawi Ahmad

  公开号：US20110015243A2

  公开（公告）日：2011-01-20

  The present invention provides for methods of using tert-butyl alcohol (TBA) co-solvent systems in the formulation and production of a pharmaceutical agent with low solubility. The present invention also provides for pharmaceutical compositions made using the novel co-solvent system. In one embodiment, the invention provides for a method of making dantrolene sodium (DS) formulation for intravenous use (DS-IV). This instantaneous reconstitution of the DS-IV product constitutes a significant improvement in the pharmacotherapy of patients undergoing malignant hyperthermia during surgery.
• US4001222A
  申请人：——

  公开号：US4001222A

  公开（公告）日：1977-01-04